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Absence of Elovl6 attenuates 
steatohepatitis but promotes 
gallstone formation in a lithogenic 
diet-fed Ldlr−/− mouse model
Motoko Kuba1, Takashi Matsuzaka1, Rie Matsumori1, Ryo Saito1, Naoko Kaga3, 
Hikari Taka3, Kei Ikehata4, Naduki Okada1, Takuya Kikuchi1, Hiroshi Ohno1, Song-iee Han1, 
Yoshinori Takeuchi1, Kazuto Kobayashi1, Hitoshi Iwasaki1, Shigeru Yatoh1, Hiroaki Suzuki1, 
Hirohito Sone5, Naoya Yahagi1, Yoji Arakawa4, Tsutomu Fujimura3, Yoshimi Nakagawa1,2, 
Nobuhiro Yamada1 & Hitoshi Shimano1,2
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) 
that can develop into liver cirrhosis and cancer. Elongation of very long chain fatty acids (ELOVL) 
family member 6 (Elovl6) is a microsomal enzyme that regulates the elongation of C12–16 saturated 
and monounsaturated fatty acids (FAs). We have previously shown that Elovl6 plays an important 
role in the development of hepatic insulin resistance and NASH by modifying FA composition. 
Recent studies have linked altered hepatic cholesterol homeostasis and cholesterol accumulation 
to the pathogenesis of NASH. In the present study, we further investigated the role of Elovl6 in the 
progression of lithogenic diet (LD)-induced steatohepatitis. We showed that the absence of Elovl6 
suppresses hepatic lipid accumulation, plasma total cholesterol and total bile acid (BA) levels in LDL 
receptor-deficient (Ldlr−/−) mice challenged with a LD. The absence of Elovl6 also decreases hepatic 
inflammation, oxidative stress and liver injury, but increases the formation of cholesterol crystals 
in the less dilated gallbladder. These findings suggest that Elovl6-mediated changes in hepatic FA 
composition, especially oleic acid (C18:1n-9), control handling of hepatic cholesterol and BA, which 
protects against hepatotoxicity and steatohepatitis, but promotes gallstone formation in LD-fed 
Ldlr−/− mice.
Currently, nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease 
worldwide1–4. NAFLD encompasses a wide spectrum of conditions associated with the over-accumulation 
of lipids in the liver, ranging from steatosis to nonalcoholic steatohepatitis (NASH), which includes hep-
atitis and fibrosis. The mechanisms of disease progression in NASH are not yet completely understood.
It has been hypothesized that the development of NASH requires ‘two hits’5. The first hit is the devel-
opment of hepatic steatosis and the second hit includes cellular stresses such as oxidative stress and 
elevated levels of proinflammatory cytokines. Recently, growing evidence suggests that simple steatosis 
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and NASH may be two separate diseases. In this ‘multiple parallel hit’ hypothesis, the accumulated lipo-
toxic/proinflammatory lipid species interact with proinflammatory factors to cause progression to NASH; 
whereas, in other cases the liver develops steatosis and remains free of inflammation6,7. Therefore, it is 
important to identify toxic lipids. Although large epidemiological studies have suggested that triglyceride 
(TG)-mediated pathways may negatively affect NAFLD8, recent evidence indicates that TGs may, in fact, 
have a protective function9,10. Several studies have shown that the dysregulation of cholesterol metab-
olism is involved in the pathogenesis of NAFLD. Epidemiological data indicate a relationship between 
increased cholesterol intake and the risk and severity of NAFLD11,12. In addition, experimental models 
have demonstrated that free cholesterol loading precipitates steatohepatitis13.
The fatty acid (FA) composition of lipid species could be another determinant of the development 
of liver injury. Elongation of very long fatty acids (ELOVL) family member 6 (Elovl6) is a microsomal 
enzyme that regulates the elongation of C12–16 saturated and monounsaturated FAs14,15. The absence of 
Elovl6 function reduces stearate (C18:0) and oleate (C18:1n-9) levels and increases palmitate (C16:0) and 
palmitoleate (C16:1n-7) levels16. In our previous study, we reported that mice with a targeted disruption 
of Elovl6 (Elovl6−/−) were protected against the development of hepatic insulin resistance16, the deteri-
oration of the insulin secretory function of pancreatic β -cells17 and macrophage foam cell formation18. 
Our findings suggest that the alteration of FA composition by Elovl6 deficiency not only affects lipid 
accumulation but also plays a vital role in a wide range of cellular functions and in disease progression.
Low density lipoprotein (LDL) receptor (LDLR)-deficient (Ldlr−/−) mice have been used in numer-
ous studies as a model for atherosclerosis. It has been reported that Ldlr−/− mice fed a high-cholesterol 
diet have increased sensitivity to inflammation, apoptosis and fibrosis of the liver19–21. In addition, 
Ldlr−/− mice have a human-like lipoprotein profile22. Therefore, Ldlr−/− mice can be used to study the 
early progression of NASH. We recently reported that atherogenic high-fat (AHF) diet-induced hepatic 
inflammation, oxidative damage and fibrosis in the liver were attenuated in Elovl6−/− mice, despite com-
parable hepatosteatosis in Elovl6−/− mice and wild-type mice23. To advance our understanding of the 
progression of NASH and to investigate the impact of Elovl6 deficiency on the development and pro-
gression of NASH, in the present study we used a lithogenic diet (LD) to induce NASH in Ldlr−/− mice.
Results
Effects of Elovl6 deficiency on body and tissue weight alterations in LD-fed Ldlr−/− 
mice. Elovl6 and LDLR deficient mice were crossed to generate mice with deficiencies of both Elovl6 
(Elovl6−/−) and LDLR (Ldlr−/−). Mice aged 11–16 weeks were fed a standard diet (SD) or an LD for 4 
weeks. On an SD, Elovl6−/−Ldlr−/− mice had similar body weight to the Elovl6+/+Ldlr−/− mice (Fig. 1A). 
The LD showed a trend to decrease body weight in Elovl6+/+Ldlr−/− mice and to increase body weight 
in Elovl6−/−Ldlr−/− mice. As a result, LD-fed Elovl6+/+Ldlr−/− mice were significantly lighter than LD-fed 
Elovl6−/−Ldlr−/− mice. Daily food intake in LD-fed Elovl6−/−Ldlr−/− mice was not significantly differ-
ent compared with LD-fed Elovl6+/+Ldlr−/− mice. The LD for 4 weeks increased liver weights in both 
Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice compared with their SD-fed counterparts, but Elovl6−/−Ldlr−/− 
mice showed less LD-induced liver weight gain compared with Elovl6+/+Ldlr−/− mice (Fig. 1B). It is well 
known that an LD increases the amount of bile, leads to supersaturation of the bile with cholesterol 
and increases susceptibility to gallstone formation. Supporting this, gallbladder weights were markedly 
increased in LD-fed Elovl6+/+Ldlr−/− mice (Fig. 1C). Conversely, absence of Elovl6 abolished LD-induced 
gallbladder enlargement, indicating a decrease in the amount of bile in Elovl6−/−Ldlr−/− mice. LD-fed 
Elovl6+/+Ldlr−/− mice exhibited significant reductions in epididymal white adipose tissue (WAT) weight 
compared with SD-fed Elovl6+/+Ldlr−/− mice (Fig. 1D). In contrast, there was no significant difference 
in WAT weight between LD-fed and SD-fed Elovl6−/−Ldlr−/− mice.
Elovl6 deficiency reduces plasma total cholesterol and bile acid levels in LD-fed Ldlr−/− 
mice. In mice fed an SD, plasma levels of total cholesterol (TC), TG, free fatty acid (FFA) and total 
bile acid (TBA) were not significantly different between Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice 
(Fig.  2A–D). After 4 weeks on an LD, plasma TC, TG and TBA levels in Elovl6+/+Ldlr−/− mice were 
markedly elevated compared with levels in SD-fed Elovl6+/+Ldlr−/− mice as a consequence of dietary 
loading of cholesterol, fat and cholic acid (CA) in the LD. However, Elovl6−/−Ldlr−/− mice were strongly 
resistant to these changes caused by the LD. Compared with LD-fed Elovl6+/+Ldlr−/− mice, LD-fed 
Elovl6−/−Ldlr−/− mice had significantly lower plasma TC, and plasma TBA levels were markedly sup-
pressed (Fig. 2A, D). High-performance liquid chromatography (HPLC) revealed that very low density 
lipoprotein (VLDL) and LDL cholesterol, the major cholesterol fraction in Ldlr−/− mice on an LD, was 
reduced and HDL cholesterol was increased in LD-fed Elovl6−/−Ldlr−/− mice compared with LD-fed 
Elovl6+/+Ldlr−/− mice (Fig. 2E).
Elovl6 deficiency suppresses hepatic lipid accumulation but promotes cholesterol crystalli-
zation and gallstone formation in Ldlr−/− mice. Photographs of the opened abdominal cavities 
of both groups on the LD show that the livers of LD-fed Elovl6+/+Ldlr−/− mice were pale, but the liv-
ers of LD-fed Elovl6−/−Ldlr−/− mice were red (Fig.  3A). However, in contrast to Elovl6+/+Ldlr−/− mice 
after 4 weeks of the LD, the LD-fed Elovl6−/−Ldlr−/− mice had opaque gallbladders and increased num-
bers of aggregated cholesterol gallstones in greenish bile. The incidence of gallstones was higher in 
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Elovl6−/−Ldlr−/− mice (80%) than in Elovl6+/+Ldlr−/− mice (37.5%) after 4-week feeding of LD (Fig. 3B). 
Microscopic examination of the gallbladder bile from LD-fed Elovl6−/−Ldlr−/− mice revealed numer-
ous large cholesterol monohydrate crystals; whereas, bile from LD-fed Elovl6+/+Ldlr−/− mice was largely 
free of cholesterol precipitates, with only occasional aggregated vesicles in most animals (Fig. 3C). The 
LD markedly increased liver TC and increased liver TG levels in Elovl6+/+Ldlr−/− mice. In LD-fed 
Elovl6−/−Ldlr−/− mice, the liver TC increase was reduced to half that observed in Elovl6+/+Ldlr−/− mice 
and there was no increase in TG levels (Fig. 3D, E). The LD increased liver TBA levels in both genotypes, 
but unlike plasma levels, there was no significant difference between the groups (Fig. 3F). Bile TC, TBA, 
phospholipid (PL), faecal TC and TBA levels were similar between LD-fed Elovl6+/+Ldlr−/− and LD-fed 
Elovl6−/−Ldlr−/− mice (see Supplementary Fig. S1 online). These results suggest that it was the change 
in hepatic lipid metabolism in LD-fed Elovl6−/−Ldlr−/− mice that suppressed hepatic cholesterol and 
triglycerides accumulation and enhanced gallstone formation, rather than a functional change in the 
gallbladder or intestine.
Histological examination of the livers revealed some inflammatory cell infiltration in SD-fed 
Elovl6+/+Ldlr−/− mice, but not in SD-fed Elovl6−/−Ldlr−/−mice (Fig.  4A). Inflammatory cell infiltration 
was exacerbated in LD-fed Elovl6+/+Ldlr−/− mice, but markedly ameliorated in LD-fed Elovl6−/−Ldlr−/− 
mice. The protection from inflammation and liver damage associated with Elovl6 deficiency was reflected 
in a significantly lower hepatic lobular inflammatory grade (evaluated by the number of inflammatory 
foci in hematoxylin & eosin [H&E]-stained liver sections) and plasma alanine aminotransferase (ALT) 
levels in LD-fed Elovl6−/−Ldlr−/− mice compared with LD-fed Elovl6+/+Ldlr−/− mice (Fig. 4B,C).
Elovl6 deficiency leads to decreased hepatic C18:1 in LD-fed Ldlr−/− mice. FA composition 
analysis identified that lack of Elovl6 modified the FA profiles of total lipid, cholesterol ester (CE), TG 
and PL fractions in the livers of Ldlr−/− mice fed an SD or an LD (Fig.  5). Compared with SD-fed 
Elovl6+/+Ldlr−/− mice, the total lipid fractions of SD-fed Elovl6−/−Ldlr−/− mice had increased C16:0 and 
C18:2n-6 and decreased C20:3n-6, C22:0 and C24:0 (Fig. 5A). Compared with LD-fed Elovl6+/+Ldlr−/− 
mice, the total lipid fractions of LD-fed Elovl6−/−Ldlr−/− mice had increased C16:0 and a tendency 
toward decreased C18:1n-9. In the CE fraction, compared with LD-fed Elovl6+/+Ldlr−/− mice, the livers 
Figure 1. Total body, liver, white adipose tissue (WAT) and gallbladder weights of Ldlr−/− mice lacking 
Elovl6. (A) Whole body, (B) liver, (C) gallbladder and (D) perigonadal WAT weights were measured in 
Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed a standard diet (SD) or a lithogenic diet (LD) for 4 weeks 
(n = 8–13 per group, *P < 0.05, **P < 0.01).
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of the LD-fed Elovl6−/−Ldlr−/− mice had a decreased relative amount of C18:1n-9, whereas the relative 
amount of C16:0 was increased (Fig.  5B). In the TG fraction, the only significant difference between 
the groups was increased C16:0 in the livers of SD-fed Elovl6−/−Ldlr−/− mice compared with SD-fed 
Elovl6+/+Ldlr−/− mice (Fig.  5C). In the PL fraction, the relative amounts of C16:0 and C16:1n-7 were 
increased in the livers of SD-fed Elovl6−/−Ldlr−/− mice compared with SD-fed Elovl6+/+Ldlr−/− mice 
(Fig. 5D). In the PL fraction in LD-fed mice, the relative amounts of C12:0, C14:0, C16:0, C16:1n-7, and 
C18:0 were increased and the relative amounts of C18:1n-9 and C24:1n-9 were decreased in the livers of 
Figure 2. Plasma lipid and lipoprotein profiles of lithogenic diet (LD)-fed Ldlr−/− mice lacking Elovl6. 
(A) Plasma total cholesterol (TC), (B) triglyceride (TG), (C) free fatty acid (FFA) and (D) total bile acid 
(TBA) levels in Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed a standard diet (SD) or an LD for 4 weeks 
(n = 8–13 per group). (E) High performance liquid chromatography lipoprotein profiles of pooled plasma 
samples from Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed an LD for 4 weeks (n = 3–4 per group). Peaks 
for very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) 
are indicated. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Elovl6−/−Ldlr−/− mice compared with Elovl6+/+Ldlr−/− mice. Despite different degrees of change depend-
ing on the lipid fraction, the overall changes in FA composition in both genotypes were consistent with 
Elovl6 enzymatic activity.
Elovl6 deficiency alters bile acid composition in the livers and bile of Ldlr−/− mice. The com-
position of BAs is associated with hepatotoxicity and cholesterol crystallization24–27. To investigate a 
potential role of Elovl6 on BA metabolism and whether BA alterations could contribute to reduced 
LD-induced liver damage and gallstone formation in LD-fed Elovl6−/−Ldlr−/− mice, the composition 
of individual BAs in the livers of Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed an SD or an LD were 
quantified by liquid chromatography/mass spectrometry (LC/MS) (see Supplementary Fig. S2 online). 
Determination of individual BA species revealed that taurocholic acid (TCA), tauro-β -muricholate 
(Tβ MCA) and tauro-ω -muricholate (Tω MCA) represent the dominant BA species in SD-fed animals of 
both genotypes. The ablation of Elovl6 in Ldlr−/− mice had little effect on liver BA composition, except that 
the ratio of tauro-α -muricholate (Tα MCA) was significantly decreased in the livers of Elovl6−/−Ldlr−/− 
mice compared with Elovl6+/+Ldlr−/− mice. Because of CA-overloading on the LD, there was a shift in 
the liver BA species in response to LD-feeding, with CA and its derivatives, TCA and taurodeoxycholic 
acid (TDCA), representing the major species in both genotypes. Elovl6 deficiency significantly decreased 
the ratio of TDCA and Tα MCA and significantly increased the ratio of glycocholic acid (GCA) in the 
livers of LD-fed Ldlr−/− mice. TDCA is increased in NASH patients26, providing a plausible biochemical 
explanation for the LD phenotype of Elovl6−/−Ldlr−/− mice. Similar BA compositional changes were seen 
Figure 3. Elovl6 deficiency suppresses lithogenic diet (LD)-induced hepatic lipid accumulation in 
Ldlr−/− mice. (A) Representative photographs of livers from Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice 
fed an LD for 4 weeks. (B) The prevalence rate of gallstones in Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice 
fed an LD for 4 weeks (n = 8–10 per group). (C) Polarizing light microscopy of gallbladder bile from 
Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed an LD for 4 weeks (magnification, × 200). (D–F) Hepatic 
total cholesterol (TC) (D), triglyceride (TG) (E) and total bile acid (TBA) (F) levels in Elovl6+/+Ldlr−/− 
and Elovl6−/−Ldlr−/− mice fed a standard diet (SD) or an LD for 4 weeks (n = 8–13 per group). *P < 0.05, 
**P < 0.01.
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in bile (see Supplementary Fig. S2 online). In contrast, lack of Elovl6 in Ldlr−/− mice had little effect on 
BA composition in plasma despite strong suppression of the total BA level. However, lack of Elovl6 in 
Ldlr−/− mice was associated with an increased concentration of chenodeoxycholic acid (CDCA) in an 
LD-fed state (see Supplementary Fig. S2 online).
Elovl6 deficiency alters LD-responsive gene expression in the livers of Ldlr−/− mice. To 
have some idea on the molecular mechanisms by which an LD results in such a striking phenotype in 
Elovl6−/−Ldlr−/− mice, mRNA expression of candidate genes in livers from mice of both genotypes fed an 
SD or an LD diet was examined using quantitative real-time polymerase chain reaction (qPCR). Genes 
involved in FA synthesis controlled by sterol regulatory element binding protein 1c (Srebf1c), such as fatty 
acid synthase (Fasn), were significantly increased and stearoyl-CoA desaturase-1 (Scd1) showed a tendency 
to increase in the livers of LD-fed Elovl6−/−Ldlr−/− mice compared with LD-fed Elovl6+/+Ldlr−/− mice 
(Fig. 6A). Expression of genes involved in TG synthesis, including glycerol-3-phosphate acyltransferase 
(Gpam) and diacylglycerol O-acyltransferase 2 (Dgat2), was slightly increased in the livers of LD-fed 
Elovl6−/−Ldlr−/− mice compared with LD-fed Elovl6+/+Ldlr−/− mice; whereas, expression of diacylglyc-
erol O-acyltransferase 1 (Dgat1) was similar in both genotypes. Expression of genes involved in choles-
terol synthesis regulated by sterol regulatory element binding protein 2 (Srebp2), including 3-hydroxy-3
-trmethylglutaryl-coenzyme A synthase 1 (Hmgcs1), was decreased, and expression of genes for choles-
terol efflux enhanced by liver X receptor α (Lxrα ) (nuclear receptor subfamily 1, group H, member 3: 
Nr1h3), such as ATP-binding cassette sub-family A member 1 (Abca1), ATP-binding cassette sub-family 
G member 1 (Abcg5), and Abcg8, was increased in response to cholesterol feeding in both groups of 
mice (Fig.  6B). Expression of acetyl-coenzyme A acetyltransferase 2 (Acat2) was increased in LD-fed 
Elovl6−/−Ldlr−/− mice compared with LD-fed Elovl6+/+Ldlr−/− mice. The enhanced expression of lipo-
genic enzymes and Acat2 in the livers of Elovl6−/−Ldlr−/− mice might compensate for the unbalanced FA 
composition. Expression of carboxylesterase 3a and 3b (Ces3a and Ces3b) was suppressed by the LD in 
Elovl6+/+Ldlr−/− mice, but was restored by the absence of Elovl6 (Fig. 6C).
Figure 4. Attenuated hepatic inflammation and liver injury in lithogenic diet (LD)-fed Elovl6−/−Ldlr−/− 
mice. (A) Representative hematoxylin and eosin (H&E)-stained sections of livers from Elovl6+/+Ldlr−/− and 
Elovl6−/−Ldlr−/− mice fed a standard diet (SD) or an LD for 4 weeks. (B) The number of inflammatory foci 
in H&E-stained sections from each animal at 20× magnification (n = 6–9 per group). (C) Plasma alanine 
aminotransferase (ALT) levels of Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed an SD or an LD for 4 weeks 
(n = 8–13 per group). *P < 0.05, **P < 0.01.
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The expression of genes associated with BA metabolism was also examined (Fig. 7A). Loss of Elovl6 
slightly decreased the expression of farnesoid X receptor (Fxr) (nuclear receptor subfamily 1, group H, 
member 4: Nr1h4) in mice on the SD but had little effect in the LD-fed mice. The LD increased the 
expression of the Fxr-target genes, liver receptor homolog-1 (Lrh1) (nuclear receptor subfamily 5, group 
A, member 2: Nr5a2) and small heterodimer partner (Shp) (nuclear receptor subfamily 0, group B, mem-
ber 2: Nr0b2), in both genotypes. The biosynthesis of BAs in the liver is controlled by multiple cytochrome 
P450 (CYP) enzymes28. The LD markedly suppressed mRNA expression of cholesterol 7α -hydroxylase 
(Cyp7a1) and sterol 12α -hydroxylase (Cyp8b1), the two key enzymes in BA synthesis, in both geno-
types. Expression of sterol 27-hydroxylase (Cyp27a1) and oxysterol 7α -hydroxylase (Cyp7b1), which are 
involved in an alternative pathway of BA synthesis, was also decreased by the LD in Elovl6+/+Ldlr−/− 
mice, but was significantly upregulated in the livers of LD-fed Elovl6−/−Ldlr−/− mice compared with 
LD-fed Elovl6+/+Ldlr−/− mice. Expression of solute carrier family 10 member 1 (Slc10a1) and solute 
carrier organic anion transporter family member 1a1 (Slco1a1), which are involved in BA uptake by 
Figure 5. Hepatic fatty acid composition. (A) Hepatic fatty acid composition for total lipids, (B) the 
cholesterol ester (CE) fraction, (C) the triglyceride (TG) fraction and (D) the phospholipid (PL) fraction 
in livers from Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed a standard diet (SD) or a lithogenic diet (LD) 
for 4 weeks. Hepatic total lipids were extracted, and the major classes of lipids were separated on a silica 
column. The lipid fractions were methyl-esterified and quantified by gas chromatography (n = 3–6 per 
group). *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:17604 | DOI: 10.1038/srep17604
hepatocytes, was suppressed by the LD in Elovl6+/+Ldlr−/− mice. Strikingly, LD-fed Elovl6−/−Ldlr−/− 
mice displayed a complete lack of Slc10a1 and Slco1a1 suppression. Expression of ATP-binding cassette 
sub-family B member 11 (Abcb11), an ABC transporter responsible for the transport of bile salt from 
hepatocytes into the bile, was significantly upregulated in the livers by the LD with greater intensity 
in Elovl6−/−Ldlr−/− mice compared to LD Elovl6+/+Ldlr−/− mice. Expression of ATP-binding cassette 
subfamily C member 1 (Abcc1), Abcc3 and Abcc4, which are involved in basolateral BA excretion, was 
markedly elevated in LD-fed Elovl6+/+Ldlr−/− mice. The expression of Abcc1 was significantly decreased, 
and Abcc4 tended to decrease (P = 0.059) in LD-fed Elovl6−/−Ldlr−/− mice compared with LD-fed 
Elovl6+/+Ldlr−/− mice. Consistently with mRNA levels, hepatic CYP7A1 protein was suppressed by LD 
feeding in both genotypes (Fig. 7B). Hepatic protein levels of CYP27a1 and SLC10A1 was also decreased 
by the LD in Elovl6+/+Ldlr−/− mice, but was upregulated in LD-fed Elovl6−/−Ldlr−/− mice compared with 
LD-fed Elovl6+/+Ldlr−/− mice.
The expression of genes involved in BA homeostasis in ileum was also examined (Supplementary Fig. 
S3). The expression levels of Nr1h4, solute carrier family 10 member 2 (Slc10a2), Abcc2, fatty acid bind-
ing protein 6 ileal (Fabp6), solute carrier family 51 beta subunit (Slc51b) and fibroblast growth factor 15 
(Fgf15) were similar between LD-fed Elovl6+/+Ldlr−/− and LD-fed Elovl6−/−Ldlr−/− mice.
Figure 6. Quantitative real-time PCR (qPCR) analysis of genes involved in steatohepatitis. 
Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice were fed a standard diet (SD) or a lithogenic diet (LD) for 4 
weeks and sacrificed following 4 h of food deprivation (n = 8–13 per group). (A) qPCR analysis of genes 
for fatty acid and triglyceride synthesis, (B) cholesterol metabolism and (C) carboxylesterase. *P < 0.05, 
**P < 0.01.
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Elovl6 deletion attenuates the inflammatory response and hepatic injury in LD-fed Ldlr−/− 
mice. Hepatic damage in LD-fed Ldlr−/− mice is associated with hepatic inflammation, oxidative 
stress and fibrosis. In agreement with histological and metabolic observations (Fig.  4), inflammatory 
response genes including tumour necrosis factor α (Tnfα), interleukin 1 β (Il-1b), toll-like receptor 4 
(Tlr4), CD14 antigen (Cd14) and secreted phosphoprotein 1 (Spp1) were upregulated in the livers of 
LD-fed Elovl6+/+Ldlr−/− mice (Fig.  8A). However, induction of these genes showed marked or a trend 
to suppression in LD-fed Elovl6−/−Ldlr−/− mice. The expression levels of genes for the nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidase complex, neutrophil cytosolic factor 1 (Ncf1), neutrophil 
cytosolic factor 2 (Ncf2) and cytochrome b-245 beta polypeptide (Cybb), were upregulated in LD-fed 
Elovl6+/+Ldlr−/− mice, but significantly decreased in LD-fed Elovl6−/−Ldlr−/− mice compared with 
LD-fed Elovl6+/+Ldlr−/− mice (Fig. 8B). The expression level of the gene for transforming growth factor 
β 1 (Tgfb1) was upregulated in LD-fed Elovl6+/+Ldlr−/− mice but suppressed in LD-fed Elovl6−/−Ldlr−/− 
mice compared with LD-fed Elovl6+/+Ldlr−/− mice (Fig. 8C). Decreased hepatic inflammation, oxidative 
stress and fibrosis in Elovl6−/−Ldlr−/− mice were further examined by measuring stresses and proinflam-
matory pathways. Elovl6 deficiency significantly attenuated LD-induced c-Jun N-terminal kinase (JNK) 
activation and α -smooth muscle actin (α -SMA) levels in Ldlr−/− mice (Fig. 8D,E).
Figure 7. Hepatic expression levels of genes involved in BA metabolism. Elovl6+/+Ldlr−/− and 
Elovl6−/−Ldlr−/− mice were fed a standard diet (SD) or a lithogenic diet (LD) for 4 weeks and sacrificed 
following 4 h of food deprivation (n = 8–13 per group). (A) qPCR analysis of genes for BA metabolism. 
*P < 0.05, **P < 0.01. (B) Immunoblot analysis of CYP7A1, CYP27A1, SLC10A1 and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) in the livers of Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed a SD 
or a LD for 4 weeks.
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Discussion
Our current findings show that the absence of the Elovl6 gene product strongly inhibits LD-induced 
accumulation of hepatic and plasma cholesterol and plasma TBA in Ldlr−/− mice. The absence of Elovl6 
also imparts striking protection from LD-induced hepatic injury by ameliorating hepatic inflammation, 
oxidative stress and stellate cell activation. The net results of these complex adaptations are a strik-
ing decrease in susceptibility to NASH, but increased susceptibility to gallstones. Normolipidemic 
Elovl6-deficient mice are known to be protected from AHF-induced NASH with no change in hepatic 
lipid content or profiles23. We have now extended the findings in Elovl6−/− mice to include protection 
from diet-induced hepatosteatosis and inflammation in dyslipidemic LDLR-deficient mice.
Feeding an LD (cholesterol and CA loading) causes accumulation of plasma, hepatic and bile cho-
lesterols in Ldlr−/− mice in response to activation of both LXR and FXR pathways and suppression of 
SREBP-2. Plasma and hepatic BAs were also elevated despite adaptive responses to hepatic handling of 
BA, such as decreased hepatic uptake, increased basolateral excretion and enhanced excretion into bile, 
Figure 8. Effects of Elovl6 deficiency on hepatic mRNA and levels of proteins involved in inflammation, 
oxidative stress and fibrosis. (A–C) Quantitative real-time PCR (qPCR) analysis of genes for inflammation 
(A), reactive oxygen species (ROS) generation (B) and fibrogenesis (C). (D) Immunoblot analysis of 
phosphorylated and total anti-phospho-c-Jun N-terminal kinase (JNK), α -smooth muscle actin (α -SMA) 
and GAPDH in the livers of Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed a standard diet (SD) or a 
lithogenic diet (LD) for 4 weeks. (E) Ratio between phosphorylated and total JNK and α -SMA and GAPDH 
on densitometry analysis (n = 2–4 per group). *P < 0.05, **P < 0.01.
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as evidenced by changes in gene expression of BA transporters and pumps to prevent overaccumula-
tion of BA in hepatocytes (as schematized in Supplementary Fig. S4). Meanwhile, the absence of Elovl6 
ameliorated LD-induced accumulation of lipids and BA in Ldlr−/− mice, indicating that Elovl6 and FA 
composition play a role in cholesterol and BA handling in hepatocytes.
A potential mechanism for the reduction in hepatic and plasma cholesterol in LD-fed Elovl6−/−Ldlr−/− 
mice is the suppression of esterification of cholesterol secondary to decreased oleate (C18:1) levels in 
the liver. Elovl6 deficiency significantly reduced oleate levels in CE and PL fractions. Because oleate, 
the major esterified cholesterol in liver, is a better substrate for ACAT than palmitate, inhibition of the 
conversion from palmitate to stearate resulting in decreased endogenous monounsaturated FAs could 
lead to reduction in esterified cholesterol. Expression of Ces3a and Ces3b was strongly suppressed by the 
LD in Elovl6+/+Ldlr−/− mice and restored in Elovl6−/−Ldlr−/− mice. Esterase and lipase activities of these 
genes might contribute to decreased hepatic lipid content in LD-fed Elovl6−/−Ldlr−/− mice. Our data are 
consistent with previous studies showing that mice harbouring a natural mutation in the Scd1 gene are 
deficient in hepatic CE and TG with decreased monounsaturated FAs (C16:1 and C18:1), and indicate 
that a reduction in hepatic oleate is likely to be a major contributor to decreased hepatic and plasma 
cholesterol29,30. It has also been reported that monounsaturated FA-containing CE levels were markedly 
elevated in the livers of mice fed a cholate-supplemented high-fat diet, but without an increase in the 
level of TG or PL in the liver, coupled with the biological and histological features of fatty liver injury31. 
Moreover, increased oleate levels have been found in the livers of NASH patients32. Recent publications 
have also indicated that hepatic cholesterol accumulation is more toxic than TG accumulation and may 
be a trigger for the progression of NAFLD13,33,34. Therefore, these data indicate that the excessive accu-
mulation of CE with oleate might contribute to liver injury and that consequent loss of oleate resulting 
from the absence of Elovl6 could be the cause of the amelioration in the current study.
Our data are consistent with our recent study using an AHF diet-fed mouse model of NAFLD/NASH, 
which demonstrated a critical role for Elovl6 in disease pathogenesis23. In that study, Elovl6−/− mice 
displayed a significant decrease in hepatic inflammation, oxidative stress, liver injury and fibrosis, but 
without amelioration of hepatosteatosis. The finding of protection against steatosis in the present study, 
which is in contrast to the previous study, is presumably because the current study protocol highlights 
cholesterol rather than TG accumulation in hepatosteatosis. LDLR deficiency activates cholesterol syn-
thesis in the liver. In addition, the LD has a lower FA content than the AHF diet. Therefore, in an LD-fed 
Ldlr−/− mouse model, the reduction of oleate by Elovl6 deficiency is further reflected in CE formation. 
Our previous study also showed a reduction in esterified cholesterol accumulation in macrophages from 
Elovl6−/− mice18.
One of the intriguing findings of the present study was the protection against LD-induced serum BA 
elevation coupled with altered expression of genes involved in hepatic BA metabolism (Cyp27a1, Cyp7b1, 
Slc10a1, Slco1a1, Abcb11 and Abcc1) in LD-fed Elovl6−/−Ldlr−/− mice. Cyp27a1 and Cyp7b1 expression 
were significantly increased in the livers of Elovl6−/−Ldlr−/− mice compared with Elovl6+/+Ldlr−/− mice 
fed on both an SD and an LD. The alternative pathway may contribute very little to overall BA synthe-
sis under normal conditions, but may become more predominant in the presence of liver disease and 
may compensate for the limitations in the classical pathway35,36. Increased Cyp27a1 and Cyp7b1 mRNA 
levels are indicative of a functional upregulation of the alternative pathway to reduce hepatotoxicity and 
the progression of liver disease to NASH37. In addition, Cyp7b1 expression was negatively associated 
with hepatic steatosis in an animal model38. Therefore, the increase in hepatic Cyp7b1 expression might 
contribute to the suppression of hepatosteatosis and liver injury in LD-fed Elovl6−/−Ldlr−/− mice. In the 
present study, the expression of Slc10a1 and Slco1a1 was increased in LD-fed Elovl6−/−Ldlr−/− mice in 
concert with decreased expression of Abcc1 and Abcc4. In support of these observations, increases in 
serum BAs were related to a decrease and an increase in Slco1a1 and Abcc4 expression, respectively, in 
the livers of mouse NASH models39. These data suggest that LD-fed Elovl6−/−Ldlr−/− mice have a greater 
ability to remove BAs from the hepatic-portal circulation than LD-fed Elovl6+/+Ldlr−/− mice.
In the present study, the LD significantly decreased the expression of Slc10a and Slco1a1 and increased 
the expression of Abcc1 and Abcc4 in the livers of Elovl6+/+Ldlr−/− mice, whereas the expression of these 
genes remained unchanged in LD-fed Elovl6−/−Ldlr−/− mice. It is well known that inflammatory sig-
nals act as potent regulators of the expression of sinusoidal and basolateral BA transporters. For exam-
ple, lipopolysaccharide (LPS) downregulates the expression of Slc10a1 and Slco1a1 and increases the 
expression of Abcc140. In addition, depletion of Kupffer cells inhibits the LPS-induced downregulation of 
Slco1a1 and upregulation of Abcc4 by attenuating the increase in TNF-α expression41,42. These previous 
observations support the present results and demonstrate one of the mechanisms by which inflammatory 
signals disrupt BA homeostasis in the liver. Because Elovl6 deficiency or modification of FA composi-
tion causes a drastic change in cholesterol metabolism, Elovl6 might also regulate BA handling (hepatic 
production, uptake, basolateral and canalicular excretion) in the enterohepatic circulation, although the 
detailed molecular mechanism is unknown.
The current findings demonstrate that LD-fed Elovl6−/−Ldlr−/− mice are more susceptible to gallstone 
formation as a result of an alteration in hepatic cholesterol metabolism that promotes hepatic free choles-
terol secretion into bile, coupled with alterations in hepatic BA metabolism. The net result of these com-
plex adaptations is a striking increase in the formation of cholesterol crystals. In the gallbladder bile, the 
solubility of cholesterol is maintained by the balance among cholesterol, bile salts and phospholipids27,43. 
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The increased biliary concentration of cholesterol in Elovl6−/−Ldlr−/− mice resulted in supersaturation, 
precipitation and crystallization of cholesterol. The FA compositional changes in the PL fraction might 
also affect the susceptibility of LD-fed Elovl6−/−Ldlr−/− mice to gallstones. Several of these conclusions 
and their underlying mechanisms warrant further examination.
In conclusion, this study demonstrates that Elovl6 plays a crucial role in the development and pro-
gression of steatohepatitis through the regulation of FA, cholesterol and BA metabolism. These findings 
are an important step forward in understanding the pathophysiology of NASH and the contribution and 
interaction of Elovl6 in hepatic inflammation associated with hepatic lipid accumulation. Further stud-
ies are needed to determine the exact contribution of Elovl6 to the risk of developing NASH and may 
provide a basis for the development of alternative therapeutic strategies and markers for diagnostic tests.
Methods
Animals and diets. Elovl6−/− mice (C57BL/6 background) were generated as described previously16. 
Ldlr−/− mice (C57BL/6J background) were purchased from the Jackson Laboratory. Elovl6−/− mice were 
crossed with Ldlr−/− mice to produce Elovl6−/−Ldlr−/− mice. The mice were housed in a pathogen-free 
barrier facility with a 12 h light/dark cycle and were given free access to food and water. Beginning at 
11–16 weeks of age, mice were fed either a standard laboratory rodent chow diet (SD) (MF; Oriental 
Yeast, Tokyo, Japan) or an LD (16.5% fat, 1.25% cholesterol, 0.5% cholic acid (CA); F2HFD1; Oriental 
Yeast) for 4 weeks [n = 13 Ldlr−/− mice fed SD (n = 5 of 11-week-old and n = 8 of 16-weeks-old), n = 8 
Elovl6−/−Ldlr−/− mice fed SD (n = 3 of 11-week-old and n = 5 of 16-week-old), n = 12 Ldlr−/− mice fed 
LD (n = 5 of 11-week-old and n = 7 of 16-weeks-old), and n = 13 Elovl6−/−Ldlr−/− mice fed LD (n = 6 of 
11-week-old and n = 7 of 16-week-old)]. Details of the LD are shown in Table S1 online. Age-matched 
male mice were used for all experiments. Mice were sacrificed during the light phase after food depri-
vation for 4 h. Plasma samples were collected from the post-orbital plexus. Tissues were isolated imme-
diately, weighed and stored in liquid nitrogen. All animal husbandry and animal experiments complied 
with the guidelines of the University of Tsukuba’s Regulations of Animal Experiments and were approved 
by the Animal Experiment Committee of the University of Tsukuba.
Plasma analysis. Plasma TC, TG, TBA and ALT were determined using commercially available assay 
kits (Wako Pure Chemicals, Tokyo, Japan). For the lipoprotein distribution analysis, plasma samples 
were analysed using an upgraded HPLC technique as previously described (Skylight Biotech Inc., Akita, 
Japan)44.
Gallbladder bile and gallstone analysis. After 4 h fasting, animals were sacrificed and cholecys-
tectomies were performed. The gallbladder was punched at the fundus to collect gallbladder bile. Bile 
samples were collected and immediately analysed by polarizing light microscopy for the presence of 
cholesterol monohydrate crystals.
Hepatic lipid analysis. Total lipids were extracted from liver tissues using Folch solution 
(chloroform-methanol, 2:1 v/v)45, dried and dissolved in 2-propanol. Hepatic lipid extracts were assayed 
for TC and TG levels using commercial assay kits for blood cholesterol and TG determination (Wako 
Pure Chemicals).
Hepatic total bile acid analysis. Hepatic TBAs were extracted from frozen tissue by homogeniza-
tion in 75% ethanol and incubation at 50 °C for 2 h as previously described46. The extracted supernatants 
were assayed using a commercially available assay kit (Wako Pure Chemicals).
Fatty acid composition of liver. Total lipids in liver were extracted using Bligh–Dyer’s procedure47, 
and TG and esterified cholesterol were separated on 500 mg silica columns (Supelclean PSA SPE Tube; 
Sigma-Aldrich Japan, Tokyo, Japan). The lipid fractions in each sample were methyl-esterified and the 
relative abundance of each FA was quantified by gas chromatography (SRL, Inc., Tokyo, Japan)48.
Histology. Livers were removed, fixed in 10% neutral buffered formalin, embedded in paraffin and 
cut into 4-μ m-thick sections for subsequent H&E staining.
RNA extraction and quantitative real-time PCR. Total RNA was extracted from livers using 
Sepasol reagent (Nacalai Tesque, Kyoto, Japan) and was reverse-transcribed using the PrimeScript RT 
Master kit (Takara Bio Inc., Shiga, Japan) according to the manufacturer’s protocols. qPCR was per-
formed using SYBR Premix Ex Taq (Takara Bio Inc.) and specific primer sets with the Thermal Cycler 
Dice Real Time System Single (Takara Bio Inc.). Primer sequences for Acat2, Nr1h3, Ces3a, Ces3b, Nr1h4, 
Nr5a2, Nr0b2, Cyp7a1, Cyp8b1, Cyp27a1, Cyp7b1, Slc10a1, Slco1a1, Abcb11, Abcc2, Abcc1, Abcc3, Abcc4, 
Slc51b, Cd14 and Cybb are summarized in Supplementary Table S2 online. Other qPCR primers used 
have been described previously16,23,49. The expression levels of mRNA were normalized to those of pep-
tidylprolyl isomerase A (Ppia) mRNA.
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Immunoblotting. Immunoblotting was performed as described previously16. Protein isolated from 
whole livers was loaded onto 10% sodium dodecyl-sulphate polyacrylamide gel electrophoresis gels 
and transferred to polyvinylidene difluoride membranes (Millipore). The membranes were probed with 
anti-CYP7A1 (Santa Cruz Biotechnology, Dallas, TX), CYP27A1, SLC10A1, α -SMA (Abcam, Cambridge, 
UK) and phospho-JNK, JNK, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling 
Technology, Denvers, MA), followed by horseradish peroxidase-conjugated anti-mouse or rabbit IgG 
(Cell Signaling Technology). Immune complexes were visualized using enhanced chemiluminescence 
(GE Healthcare).
Statistical analysis. Results are expressed as mean ± SEM. Data between groups were analysed by 
Student’s t-test. Differences were considered significant at P < 0.05.
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Supplementary Table S1 
 
The Composition of the Lithogenic Diet (LD) 
 
Composition       % 
 
Cacao butter    7.500 
Cholesterol    1.250 
Cholate     0.500 
Milk casein                      7.500 
Cellulose     1.250 
Vitamin mix        1.000 
Mineral mix           1.000 
Sucrose           1.625 
Glucose                            1.625 
Dextran                           1.625 
Choline chloride    0.125 
Lard     3.000 
CRF-1                            72.000 
  
Total       100.000 
  
  
Supplementary Table S2 
 
Sequence information for the quantitative Real-time PCR analysis 
Gene 
name 
Forward primer 
(5’ to 3’) 
Reverse primer 
(5’ to 3’) 
Acat2 CCCGTGGTCATCGTCTCAG GGACAGGGCACCATTGAAGG 
Nr1h3 AGCAACAGTGTAACAGGCGCT ACGATGGCCAGCTCAGTAAAGT 
Ces3a ACTGGGACCTCTTCGGTTCT GGTGAATCTGCTGTTGCTCA 
Ces3b CACAGACCGCATGGTAAATG TTGATGCTGGCATCTCTCAC 
Nr1h4 CTCTGCTCACAGCGATCGTC CACCGCCTCTCTGTCCTTGA 
Nr5a2 ATACAAACTCCCGCTGATCG AAGTCGCGTTCAACAACCTC 
Nr0b2 CGATCCTCTTCAACCCAGATG AGGGCTCCAAGACTTCACACA 
Cyp7a1 GCTGAGAGCTTGAAGCACAAGA TTGAGATGCCCAGAGGATCAC 
Cyp8b1 CTAGGGCCTAAAGGTTCGAGT GTAGCCGAATAAGCTCAGGAAG 
Cyp27a1 CCAGGCACAGGAGAGTACG GGGCAAGTGCAGCACATAG 
Cyp7b1 AGCCGATTATCAGCGAAAGCC GCATCCAAAGGTTTGCCTTGT 
Slc10a1 AGGGGGACATGAACCTCAG TCCGTCGTAGATTCCTTTGC 
Slco1a1 ACTCCCATAATGCCCTTGG TAATCGGGCCAACAATCTTC 
Abcb11 CAATGTTCAGTTCCTCCGTTCA TCTCTTTGGTGTTGTCCCCATA 
Abcc1 GATGGCTCCGATCCACTCT AGGTAGAAACAAGGCACCCA 
Abcc2 TCCAGGACCAAGAGTTTGC TCTGTGAGTGCAAGAGACAGGT 
Abcc3 TGAAGACTGCACCGTACTGAC AGAAACCCTTGGAATGCATC 
Abcc4 AGCTTCAACGGTACTGGGATA TCGTCGGGGTCATACTTCTC 
Slc51b AGAGAAAGCTGCAGCCAATG CCAGGACCAGGATGGAATAA 
Cd14 GAAGCAGATCTGGGGCAGTT CGCAGGGCTCCGAATAGAAT 
Cybb TTGGGTCAGCACTGGCTCTG TGGCGGTGTGCAGTGCTATC 
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Supplementary Figure Legends 
Supplementary Figure S1.  Bile and fecal lipid profiles of LD-fed Ldlr−/− mice lacking Elovl6. 
(A) Bile total cholesterol (TC), total bile acid (TBA), and phospholipid (PL) levels (n = 3–8 per 
group) and (B) fecal TC and TBA levels (n = 7–10 per group) of Elovl6+/+Ldlr−/− and 
Elovl6−/−Ldlr−/− mice fed a SD or a LD for 4 weeks. 
 
Supplementary Figure S2.  Bile acid composition in (A) liver, (B) bile, and (C) plasma  in 
Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice fed a SD or a LD for 4 weeks (n = 3–9 per group). 
individual BA species were examined by LC/MS. CA, cholic acid; GCA, glycocholic acid; 
DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; TCA, taurocholic acid; CDCA, 
chenodeoxycholic acid; αMCA, alpha-muricholic acid; βMCA, beta-muricholic acid; ωMCA, 
omega-muricholic acid; UDCA, ursodeoxycholic acid; HDCA, hyodeoxycholic acid; TCDCA, 
taurochenodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; THDCA, 
taurouhyodeoxycholic acid; TαMCA, tauro-α-muricolic acid; TβMCA, tauro-β-muricolic acid; 
TωMCA, tauro-ω-muricolic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GDCA, 
glycodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; GUDCA, glycoursodeoxycholic 
acid; GHDCA, glycouhyodeoxycholic acid.  ∗ P < 0.05, ∗∗ P < 0.01. 
 
Supplementary Figure S3.  Quantitative real-time PCR (qPCR) analysis of genes involved in 
bile acid homeostasis in the ileum. Elovl6+/+Ldlr−/− and Elovl6−/−Ldlr−/− mice were fed a SD or a 
LD for 4 weeks and sacrificed following 4 h of food deprivation (n = 4–7 per group). qPCR 
analysis of genes for (A) Elovl6, Nr1h4, Slc10a2, Abcc2, Fabp6, Slc51b and (B) Fgf15. ∗ P < 
0.05, ∗∗ P < 0.01. 
 
Supplementary Figure S4.  Proposed mechanism of Elovl6-mediated metabolic alteration in 
LD-induced liver injury and gallstone formation.  
 
 
 
 
 
 
 
 
 
 
Supplementary Methods 
Individual bile acid analysis by Liquid Chromatography/Mass Spectrometry  
We determined individual bile salt compositions by liquid chromatography/mass spectrometry. 
BA standards were purchased from Sigma. For liver samples, approximately 100 mg of liver 
was homogenized in 2.5 volumes of H2O. d4-CA (Internal standard: IS) and 400 μl of ice-cold 
ethanol were added to 200 μl liver homogenate. Samples were vortexed, centrifuged, and the 
supernatants were evaporated before being reconstituted in a 200 μl of 50:50 solution of ethanol 
and water. For plasma samples, 450 μl of ice-cold EtOH was added to 50 μl plasma-spiked with 
IS, vortexed, and centrifuged. The supernatants were evaporated and reconstituted in a 100 μl of 
50:50 solution of ethanol and water. Bile samples were diluted 100- and 2000-fold with a 50:50 
solution of ethanol and water, and IS was added. The LC system used was a HPLC (Gilson) 
equipped with an autoinjector. The HPLC was connected to a TSQ Quantum Ultra (Thermo 
Scientific). Individual BAs were eluted with gradient at a 0.2 ml/min flow rate for a mobile 
phase A (10 mM AcONH4 in H2O) and mobile phase B (10 mM AcONH4 in a 23:17 solution of 
CH3CN and ethanol). The samples were eluted with 80% mobile phase A and 20% mobile phase 
B for an initial 5 min after injection, and then with a linear gradient of mobile phase B of 20% 
to 75% over 55 min, which was held for 5 min. The injection volume of all samples was 5 μl. 
Quantitative analysis was performed in negative ionization mode using the selected reaction 
monitoring transitions specific for each BA. 
